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The shortage of deceased donors led to an increase of living donor kidney (LDK) transplan-
tations performed in the presence of donor-specific antibodies (DSA) or ABO incompatibility
(ABOi) using various desensitization protocols.
Methods
We herein analyzed 26 ABOi and 8 Luminex positive DSA patients who were successfully
desensitized by anti-CD20, antigen-specific immunoadsorption and/or plasmapheresis to
receive an LDK transplant. Twenty LDK recipients with non-donor-specific HLA-antibodies
(low risk) and 32 without anti-HLA antibodies (no risk) served as control groups.
Results
1-year graft survival rate and renal function was similar in all 4 groups (creatinine: 1.63 ± 0.5
vs 1.78 ± 0.6 vs 1.64 ± 0.5 vs 1.6 ± 0.3 mg/dl in ABOi, DSA, low risk and no risk group). The
incidence of acute T-cell mediated rejections did not differ between the 4 groups (15% vs
12, 5% vs 15% vs 22% in ABOi, DSA, low risk and no risk), while antibody-mediated rejec-
tions were only found in the DSA (25%) and ABOi (7.5%) groups. Incidence of BK nephrop-
athy (BKVN) was significantly more frequent after desensitization as compared to controls
(5/34 vs 0/52, p = 0.03).
Conclusion
We demonstrate favorable short-term allograft outcome in LDK transplant recipients after
desensitization. However, the desensitization was associated with an increased risk of
BKVN.
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Introduction
The considerable shortage of organ donors and increasing number of patients with end-stage
renal disease has led to an extended waiting time for potential renal allograft recipients. In
addition, approximately 30% of patients on the kidney waiting list are sensitized to HLA anti-
gens of potential donors facing a significant increased waiting time [1]. The introduction of
solid phase assays, such as the Luminex technology, which allows a more sensitive and specific
identification of donor-specific anti-HLA antibodies (DSA), may impact the organ allocation
process even further, in that even more patients are considered to be sensitized and rejected as
recipients [2;3]. However, the impact of DSA detected only by solid phase assays on transplant
outcome remains under debate [4]. While the identification of DSA in the presence of a nega-
tive complement depending cytotoxicity (CDC) in pre-transplant sera were linked with
increased immunogenic graft loss in retrospective analysis [5;6], smaller prospective series
questioned their relevance [7;8]. In particular, the degree of mean fluorescent intensity (MFI)
that is of clinical relevance remains unclear, with large retrospective series showing no apparent
difference in graft loss in recipients with DSA at an MFI< 3000 [9]. Therefore, several centers
developed desensitization protocols to allow immunized patient to receive a kidney from a
donor across the HLA barrier. Using different therapeutic strategies with new immunosuppres-
sive medications, modern apheresis techniques and/or antigen-specific immunoadsorption,
promising short-term outcomes have been reported [10–12]. Furthermore, ABO-incompatible
(ABOi) living kidney donor (LDK) transplantation has become a popular alternative to expand
the donor pool [13].
However data from those studies have been difficult to interpret or compare because of het-
erogenecity among immunologic testing techniques, DSA levels, desensitization strategies, and
demographic and clinical characteristics of donor and recipient populations. We therefore
aimed to reevaluate our own practice by assessing 1-year graft outcome after desensitization in
renal transplant recipients who received a kidney from a living donor across blood group and/
or HLA barriers in comparison to two matched control groups with low immunological risk.
We furthermore aimed to evaluate the impact of the intensified immunosuppressive regiment
on the rate of BK virus infections.
Methods
Study design and patients
We conduct a retrospective cohort study with 91 adult patients (> 18 years) who received a
LDK between January 2007 and June 2012 at our center. The study was approved by the ethics
board of the Ludwig-Maximilians-University Munich. The patients gave their written consent.
This consent procedure was also approved by the ethics committee of the Ludwig-Maximi-
lians-University Munich (Approval number 513–12). The patients selected for the study had
either Luminex-detected donor-specific antibodies with a MFI> 3000 or DSA with a
MFI< 3000 but a positive CDC B-cell and/or Luminex crossmatch prior to transplantation
(DSA group, n = 8) or had received a kidney from an ABO blood group incompatible donor
(ABOi group; n = 26). The patients selected for the control groups were recipients, who
received a living-donor kidney during the same time period and were maintained on the same
long-term tripple immunosuppressive regiment and had Luminex-detected non-donor-spe-
cific antibodies (nDSA) (low risk group, n = 20) or no anti HLA-antibodies (no risk group,
n = 32). All patients had a negative T-cell CDC crossmatch. However, within the DSA group
4/8 patients had a positive B-cell CDC crossmatch and 6/8 patients had a positive Luminex
crossmatch before desensitization.
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HLA-antibody screening and C1q assay
Recipients were screened for the presence of HLA-antibodies before transplantation and dur-
ing the routine follow-up by means of Luminex (Life Screen Deluxe, Gen-Probe, USA). In posi-
tively screened patients antibody specificity in relation to the donor was confirmed by Single
Antigen Beads (SAB) (LSA, Gen-Probe, USA). An MFI of> 3000 was used as cut-off. Recipi-
ents in the DSA group were screened for C1q binding HLA-antibodies by C1q-SAB assay
using Luminex (LabScreen, One lambda, USA).
Isoagglutinine titers
Anti-donor isoagglutinin titers were measured by a microtube column agglutination technique,
using the Diamed-Coombs-Anti-IgG1 and Diamed-ID-NaCl1 systems (DiaMed Diagnostika
Deutschland, Germany).
Immunosuppressive protocol
Maintenance immunosuppression in all patients consisted of a triple drug therapy including
either tacrolimus (trough levels 8–12 ng/mL during the first 3 month, 6–10 ng/ml during
month 3–6, 4–8 ng/ml during month 6–12 post-transplantation) or ciclosporin (trough levels
160–200 ng/mL during the first 3 month, 120–160 ng/ml during month 3–6, 80–120 ng/ml
during month 6–12 post-transplantation), mycophenolatemofetil (1000 mg orally twice daily)
and methylprednisolone (tapered to the dose of 5 mg by 6 month post-transplantion). Patients
received desensitization and/or induction therapy according to the following protocol
(Table 1):
Anti-infective prophylaxis
All patients with a high-risk CMV constellation (D +/R -) received a prophylaxis with valganci-
clovir for 3 months post-transplantion. Furthermore, oral PcP prophylaxis (trimethoprim/sul-
famethoxazole 160 mg/800 mg, 3 times a week) was administered 6 months post-transplant to
every patient.
Antigen-specific immunoadsorption and plasma exchange
Immunoadsorption (IA) was performed using a commercially available apheresis device (Octo
Nova1, Diamed Medizintechnik, Germany) and hollow-fibre plasma separators (Plasmaflow1
OP-05, Asahi Kasei Medical Ca. LTD, Tokyo, Japan). Plasma was passed through the antigen-
specific carbohydrate column (Glycosorb A/B1, Glycorex Transplantation AB, Sweden). Pre-
operatively ABOi recipients underwent IA every other day until IgG anti-A/B titers were 1:8 or
Table 1. Protocols for desensitization and immunosuppressiv therapy.
Group Rituximab Desensitization Induction Therapy Maintenance Therapy
DSA + Plasmaexchange ATG +
ABOi + Antigen-specific IA ATG +
low-risk - - ATG/Basiliximab +
no risk - - - +
Rituximab (MabThera1, Roche Pharmaceuticals, Basel, Switzerland): 375 mg/m2, 4 weeks prior to transplantation; ATG Fresenius1 (Fresenius, Munich,
Germany): 4 mg/kg, once a day, day 0–4 post transplantation; Basiliximab (Simulect1, Novartis, Basel, Switzerland): 20 mg day 0 and day 4 post
transplantation, Antigen-specific Immunoadsorption (Glycosorb A/B@ columns, GlycorexTransplantation AB, Lund, Sweden)
doi:10.1371/journal.pone.0146075.t001
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less. Postoperative IA was only performed if anti-A/B IgG titers exceeded 1:8 in the first and
1:16 in the second postoperative week. Plasma exchange (PE) was performed using the same
commercially available apheresis device and hollow-fibre plasma separators. Each patient
within the DSA group was cleared for transplantation after receiving standard 6 PE. At each
session one-plasma volume was replaced by 5% serum albumin.
BKV
Systematic BKV screening using a polymerase-chain-reaction (PCR) assay was routinely per-
formed at baseline (transplantation) and every three months thereafter. The cut off used to
considerer the PCR as a positive viremia for BK virus was 1,000 copies/ml. In patients with
diagnosed BK viremia and/or BK nephropathy (BKVN) immunosuppression was reduced, in
that MMF was slowly tapered to half the dose and blood through levels of tacrolimus were
reduced (goal 4–5 ng/ml). In the event of BKVN with concomitant acute rejection MMF was
replaced by leflunomide. Leflunomide was administered with a loading dose of 100 mg for 3
days, followed by maintenance dose of 20 mg/d, adjusted for blood levels of 50–100 μg/ml.
Biopsies/Rejections
Allograft biopsies were taken when renal graft function was impaired or BK viremia developed.
Rejection was determined according to the diagnostic criteria proposed at the 2007 Banff Con-
ference [14]. C4d staining was routinely performed in paraffin sections of all biopsies. C4d pos-
itive staining in peritubular capillaries (PTC) was evaluated semi-quantitatively as follows:
minimal (<10% of PTC), focal (11–50% of PTC) and diffuse (>50% of PTC) [15]. The diagno-
sis of BK nephropathy was based on histologic features in combination with positive staining
for SV40.
Demographic and clinical information
The following parameters were evaluated:
1. Donor variables: age, gender, relationship to recipient, CMV and EBV status
2. Recipient characteristics: age, gender, cause of kidney failure, time on dialysis, previous
transplants, human leukocyte antigen (HLA) mismatch, panel reactive antibodies (>10%),
anti-HLA-antibodies, CMV- and EBV-status, bodymass index (BMI) [kg/m2], anti-donor
isoagglutinine IgG titers, number of performed PE or IA therapies.
3. Perioperative factors: cold ischemia time
4. Post-transplant factors: serum creatinine levels and calculated glomerular filtration rate
(GFR) by MDRD; proteinuria, defined as> 500 (mg)protein/(g)creatinine ratio in spot
urine; loss of GFR within the first year after transplantation (GFRat 1 month—GFRat 12 month),
number of rejections (confirmed in all cases by graft biopsy) and number of BK-virus infec-
tions or nephropathy (serological or biopsy proven) within 12 month
Statistics
Statistical analysis was performed using Sigma Plot. Data are given as mean values ± standard
deviation and n represents the number of patients per group. To calculate differences between
group we utilized the Mann-Whitney-U-test for continuous variables and ChiSquare-test for
categorical variables. A value of probability of less than 0.05 was defined to indicate statistical
significance.
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Results
Patient characteristics
The patient characteristics are shown in Table 2. No significant differences were noted in the
age and sex of donors and recipients, relationship between them, kidney diseases and the num-
ber of HLA mismatches. As expected the number of prior transplants was significantly higher
in the DSA group (75%) and low risk group (40%) resulting in significantly higher PRA (panel
reactive antibodies) IgG levels as in the no risk and ABOi group. Interestingly, time on dialysis
was also higher in the DSA group.
Desensitization within the ABOi and DSA group
The median anti-donor IgG isoagglutinine titer in the ABOi group was 1: 512 (range 1:2 up to
1:1024) prior of treatment. The 26 patients underwent a mean of 4 ± 3 IA sessions before sur-
gery. Five of 26 patients (19.2%) patients required an IA session post-transplantion because of
a rise in isoagglutinine titers. All 5 patients had a higher titer before transplantation.
Within the DSA group 1 patient was desensitized due to DSA against HLA-class I only, 1
patient due to DSA against HLA-class I and II, while the remaining 6 patients were positive for
DSA against HLA-class II only. The mean DSA against HLA-class I MFI was 1000 ± 1927 and
the mean DSA against HLA-class II MFI was 9100 ± 7088 before desensitization. With 6 rou-
tine PE treatments the mean DSA against HLA-class I MFI could be reduced to 200 ± 385
while the mean DSA against HLA-class II MFI remained significantly elevated by 6800 ± 7484.
Four patients were transplanted with DSA against HLA-class II MFI above 3000.
Table 2. Patient and donor characteristics.
AB0i DSA low Risk no Risk p-value
Number (n) 26 8 20 32
Age recipient (years) 49.5 ± 15.3 45 ± 5.6 44.3 ± 17 46 ± 13 ns
Female recipient (%) 38.5 37.5 30 47 ns
BMI recipient (kg/m2) 24.1 ± 4.3 24.9 ± 5.1 23.1 ± 3.9 25 ± 4 ns
Kidney Disease ns
Diabetes 2 1 0 1
Hypertension 4 0 2 4
Glomerulonephritis 8 7 14 20
ADPKD 4 0 2 2
Amyloidosis 2 0 0 0
Genetic 1 0 1 1
Unknown 5 0 1 5
Time on dialysis (days) 587 ± 529 836 ± 635 499 ± 381 512 ± 210 ns
Preemptive Tx (%) 27 0 5 31 ns
HLA Mismatch (n) 3.5 ± 1.6 3.0 ± 1.5 3.1 ± 1.6 3.1 ± 1.4 ns
Re-Transplantation (%) 15 75 40 3 < 0.0001
PRA IgG > 10% (%) 11 100 60 0 < 0.0001
Age donor (years) 57.7 ± 10.5 53.1 ± 9.5 54.6 ± 10.7 57 ± 11 ns
Female donor (%) 69 37.5 80 62.5 ns
Cold ischemia time (hours) 1 ± 0.0 1 ± 0.0 1 ± 0.1 1 ± 0.0 ns
All values represent means ± SD, unless otherwise stated. Abbreviations: HLA: human leukocyte antigen; PRA: panel reactive antibody; BMI: body mass
index.
doi:10.1371/journal.pone.0146075.t002
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Patient and graft survival
Patient survival at 12 months follow-up was 100% in all 4 groups, while graft survival was
100% in the ABOi, DSA and no risk and 95% in the low risk group. 1 patient in the low risk
group lost his graft within 1 week after transplantation because of recurrence of disease
(FSGS).
Graft function
Renal function, as assessed by serum creatinine levels and estimated GFR (MDRD formula) at
10 days, 1, 4, and 6 months (data not shown) was similar in all 4 groups, while it was slightly
reduced in the DSA group at 12 months after transplantation (creatinine: 1.78 ± 0.6 mg/dl;
GFR: 42.6 ± 10 ml/min) as compared to the ABOi, low risk and no risk group (creatinine:
1.63 ± 0.5 vs 1.64 ± 0.5 vs 1.6 ± 0.3 mg/dl; GFR: 48.05 ± 18 vs 48.5 ± 13 vs 45.4 ± 10 ml/min,
respectively). (Fig 1) However, the difference was not statistically significant. While no patient
in the no risk group and ABOi group developed significant proteinuria defined as> 500 mg
protein/ g creatinine ratio, 1 DSA (2950 mg protein/g creatinine) and 2 low risk patients
(530 mg protein/g creatinine and 1010 mg protein/g creatinine, respectively) showed signifi-
cant proteinuria (p = 0.935).
Loss of graft function within 12 months
To estimate loss of renal function within the first year after transplantation we evaluated the
GFR slope (GFR at 1 month−GFR at 12 month). Renal function increased in the AB0i (GFR differ-
ence: + 6.1 ± 11,8 ml/min), low risk (GFR difference: + 2,1 ±12,5 ml/min) and no risk group
(GFR difference: + 4,5 ± 12,5 ml/min), while it significantly decreased in the DSA group (GFR
difference: -3,1 ± 7,5 ml/min, p = 0.023). (Fig 2)
Rejections
Fig 3 illustrates that the number of patients experiencing 1 or more rejections (including bor-
derline cases) was higher in the DSA group (37.5%) in comparison to the ABOi (23%), low risk
(15%) and no risk group (22%). However, the difference did not reach statistical significance
(p = 0.641). While the number of T-cell mediated rejections was comparable in all 4 groups
(15% vs 12,5% vs 15% vs 22% in ABOi, DSA, low risk and no risk group, p = 0.868) antibody-
mediated rejection (AMR) only occurred in 2 DSA (25%) and 2 ABOi patients (8%). Of note,
Fig 1. Renal function at 12 month.Renal function, as assessed by serum creatinine levels and estimated GFR (MDRD formula) at 12 months after
transplantation.
doi:10.1371/journal.pone.0146075.g001
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2 additional ABOi recipients developed a T cell mediated rejection after reduction of immuno-
suppression due to BKVN.
HLA antibody screening post-transplant
Persistence of pre-existing DSA. Pre-existing DSA against HLA-class II levels with a MFI
value above 3000 were still detectable in 6 (75%) patients including those 3 who experienced an
acute rejection episode. In 50% of patients the antibodies were able to fix complement C1q.
However, C1q-DSA did not seem to predict an acute rejection. (Table 3)
Persistence of pre-existing nDSA. In the low risk group we found evidence of persistent
nDSA in 5/17 patients. All of these patients were biopsied due to impaired renal function.
However, none of them experienced an acute rejection.
Development of denovo DSA. Eight patients developed denovo DSA during follow up
(2/24 ABOi, 3/17 low-risk and 3/29 no-risk patients). Only 1 ABOi recipient showed histologic
evidence of AMR.
Development of denovo nDSA. Denovo nDSA could be detected in 2 ABOi (8,4%), 2 low
risk (11,8%) and 4 no risk patients (13,7%). 1 ABOi recipient developed a Banff 3 borderline
lesion, 1 low risk patient developed a Banff 4 Ia rejection and 1 no risk patient developed a
Banff 3 borderline lesion.
Fig 2. Loss of renal function within the first year. The GFR slope within the first year was assessed
according to the following formula: GFR at 1 month−GFR at 12 month.
doi:10.1371/journal.pone.0146075.g002
Fig 3. Incidence of rejection. The number of patient experiencing 1 or more biopsy proven rejections (including borderline cases with impaired renal graft
function) according to the Banff 97 classification: 2 = antibody mediated rejection (AMR), 3 = borderline lesion, 4 I and 4 II = acute cellular rejection.
doi:10.1371/journal.pone.0146075.g003
Outcome after Desensitization in HLA or ABOi Renal Transplantation
PLOS ONE | DOI:10.1371/journal.pone.0146075 January 5, 2016 7 / 12
In summary, the persistence of DSA was associated with a frequency of 50% (3/6 patients)
acute rejection episodes, in comparison to 37,5% in recipients with denovo nDSA (3/8 patients)
and 12.5% (1/8 patients) in recipients with denovo DSA.
BKV
Overall 6/86 patients (6,9%) developed a significant BKV (median 165500 copies/ml) at a median
of 192 ± 65 days after transplantation leading to BKVN in 5/86 patients (incidence of 5.8%). All
patients with BK-viremia/BKVN were within the ABOi (4/26) and DSA (2/8) group while no
patient in the no risk or low risk group showed BK- viremia (0/52) (p = 0,03). BK-viremia/
BKVN developed in 2/6 patients (33%) after anti-rejection therapy consisting of steroids, plasma-
pheresis, IVIG and Rituximab. In patients with diagnosed BK-viremia and/or BKVN immuno-
suppression was reduced. Two patients experienced biopsy-proven acute rejection thereafter.
They were treated by steroid pulse therapy and MMF was replaced by leflunomide. Renal func-
tion 12 month after transplantation was reduced in patients with BKVN (creatinine 2,22 ± 0,67
mg/dl) in comparison to those without signs of BKVN (creatinine 1,59 ± 0,44 mg/dl) (Table 4).
Discussion
In this report, we present our experience in patients that underwent desensitization due to
ABO or HLA incompatible living donor kidney transplantation in comparison to two control
Table 3. Immunologic characteristics in the DSA group.
Pat DSA C1q B celXM LuminexXM MFI 1 MFI 2 persistentDSA Rejection Creatinine Proteinuria
1 DQ2 No Negative Negative 5.000 2.000 Yes 4IIb) 1,4 No
2 DR15 No Negative Positive 9.000 200 Yes No 1,2 No
3 A2 No Positive Positive 5.000 600 No No 1,4 No
4 DQ5 Yes Negative Negative 20.000 17.000 Yes No 2,3 No
5 B7 &DR16 Yes Positive Positive 9.000 6.000 Yes 2 2,7 Yes
6 DQ6 No Positive Positive 1.800 200 No No 1,4 No
7 DR13 Yes Negative Positive 18.000 17.000 Yes 2 2,3 No
8 DR3 Yes Positive Positive 12.000 10.000 Yes No 1,8 No
DSA: donor specific anti-HLA antibody, XM: crossmatch, Tx: Transplantation, MFI: Mean Fluorescence Intensity, MFI 1: before PE, MFI 2: at Tx; PE:
Plasma Exchange, Rejection: according to Banff classification; Banff: Banff classification, 4IIb: cellular, 2: humoral;. Proteinuria: > 500 mg protein/g
creatinine at 12 month post tx, creatinine mg/dl at 12 month post tx, C1q: C1q binding donor-specific anti-HLA antibodies,
doi:10.1371/journal.pone.0146075.t003







BKVN Intervention to BKVN Rejection post intervention
1 ABOi No No 265 590.000 Yes Red. IS No
2 ABOi No No 66 430.000 Yes Red. IS Yes
3 ABOi 2 (humoral) Steroids, ATG, PE 192 490.000 Yes Red. IS No
4 ABOi No No 174 350.000 Yes Red. IS Yes
5 DSA 2 (humoral) Steroids, Rituximab 202 770.000 Yes Switch No
6 DSA 2 (humoral) Steroids, ATG, PE 254 1.500 No Red. IS No
Tx: Transplantation, BKVN: BK virus nephropathy, ATG: Anti-thymocyte globulin, PE: Plasma Exchange, Red IS: Reduction in immunosuppression;
Switch: switch from MMF to Leflunomid.
doi:10.1371/journal.pone.0146075.t004
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collectives. Using desensitization with anti-CD20, antigen-specific IA and/or PE we demon-
strated favorable short-term allograft survival and function after ABOi renal transplantation.
However, in patients with Luminex-detected DSA pre-transplant we noted an increase in rejec-
tion episodes and a significant decline in renal function 12 months after transplantation. Fur-
thermore, we noted an increase in the rate of BK virus infections after the intensified
desensitization protocol in ABOi and HLA recipients.
Our results are in line with the extended experience of other groups showing that ABO
incompatible kidney transplantation is a reasonable way to extend the donor pool. Takahashi
K et al recently reported excellent patient (91%) and graft (83%) survival 9 years after kidney
transplantation within the largest cohort of 1427 ABO incompatible recipients with the longest
follow-up of more than 20 years [16].
In the context of LDK transplant recipients with DSA Klein et al. showed that desensitiza-
tion results in good outcomes with low rate of side effects [17]. In contrast, Bentall et al., also
showed an impaired 5 year graft survival in kidney allograft recipients with a positive pre-
transplant flow cytometric crossmatch who were desensitized by PE and IVIG in comparison
to a crossmatch-negative control group (70.7% vs. 88.0%) [18]. This is in line with our own
results showing a reduced renal function with a loss of GFR of 3.1 ml/min within the first year
after transplantation across HLA barriers as compared to the controls. Furthermore, we experi-
enced more rejections in the DSA group with the persistence of DSA beeing the greatest risk to
develop a rejection in our cohort. Comparably, Bagnaso et al experienced an incidence of clini-
cal and subclinical rejections of 66% in serial graft biopsies in HLA-incompatible kidney allo-
graft recipients with pre-transplant DSA in the first year [19]. Furthermore, patients with DSA
post-transplantation had a significant higher probability to develop transplant glomerulopathy.
However, we were unable to show an association of rejection episodes with high MFI DSA
titers, C1q-binding DSA and/or a positive Luminex and/or B-cell crossmatch, although this
might be an effect of our small sample size. In addition, C1q-binding capacity and the MFI
DSA titer did not correlate with CDC crossmatch, as patient number 6 had a very low anti-DQ
titer, which was C1q negative, but a positive CDC B-cell XM. He was desensitized due to the
positive CDC- B-cell XM. The positive CDC XMmight be caused by non-HLA antibodies.
Thus while expanding the donor pool by transplanting over HLA barriers one should consider
the higher immunologic risk. On the other hand, it has been demonstrated that the longer wait-
ing time on dialysis in immunized versus non immunized recipients is a major risk factor for a
poor patient outcome after kidney transplantation [20]. Furthermore, LDK transplantation
after desensitization appears beneficial for the patient, in that survival rates in desensitized
LDK transplant recipients were strikingly higher than in dialysis patients waiting for a HLA
compatible deceased donor organ despite a diminished graft function (80.6% vs 49.1%) [21].
However, the impact of potential side effects of desensitization such as infections or malig-
nancies is still unknown. The BKV is a member of the polyoma virus family with a seropreva-
lence between 46% - 94% in the general population [22]. With the renal tubular system being
the main target for virus infiltration reactivation of the latent BKV in kidney allograft recipients
receiving immunosuppression can cause BK specific interstitial nephritis. It mostly develops
within the first year and can result in a 50% rate of graft loss [23–26]. A recent increase in prev-
alence BKVN (1% - 10%) has been attributed, in part, to the use of more potent immunosup-
pressive regimens and an increased use of antirejection therapy [27;28]. However, it seems the
overall intensity of immunosuppression, rather than one specific drug, leading to an increased
risk [29]. In line with this theory, we noted a significant increase in the incidence of BKVN in
patients after desensitization in comparison to the control groups. The intensified immunosup-
pressive therapy due to the desensitization and/or the more frequent antirejection therapy dur-
ing the first year may have rendered those groups more susceptible for BKV reactivation.
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However, another reason might be a lower maintenance therapy within the low risk groups.
These data are in agreement with recent reports including our own showing an increased inci-
dence of BKVN (20–25%) after desensitization in ABOi or HLA incompatible transplant recip-
ients [30–32].
In conclusion we demonstrate impaired short-term allograft outcome in LDK transplant
recipients undergoing desensitization for preformed DSA (HLA-incompatible). However,
regarding the increased rejection rate we did not succeed in identifying any predictive serologic
parameter. Prospective and multicenter studies are needed to standardized desensitization
therapies and to proof the predictive values of MFI cut-off or C1q-binding assays.
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